| MMM |
Report |
Operating EPS (Q2 2026) |
BEAT |
pred ~$2.29 vs. cons $2.25 |
MEDIUM |
| MMM |
Report |
Net sales (Q2 2026) |
BEAT |
pred ~$6.38B vs. cons $6.31B |
MEDIUM |
| MMM |
Report |
Organic sales growth (Q2 2026) |
BEAT |
pred ~3.6% vs. cons 3.22% |
MEDIUM |
| MMM |
Guide |
Organic sales growth (FY 2026) |
BETTER |
guide ~3.2% vs. cons 2.97% |
MEDIUM |
| MMM |
Guide |
Operating EPS (FY 2026) |
UNCHANGED |
guide ~$8.65-$8.80 vs. cons $8.75 |
LOW |
| MMM |
Guide |
Organic sales growth (Q3 2026) |
BETTER |
guide ~3.6% vs. cons 3.45% |
LOW |
| MMM |
Return |
Day-1 residual (stock − beta × S&P 500) |
+5.0% |
— |
LOW |
| MMM |
Return |
5-day cumulative residual |
+6.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — estimate upgrades should follow a real contingency release and stronger organic-growth outlook. |
LOW |